Anti-cancer stem cell monoclonal antibodies (OncoMed)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-cancer stem cell monoclonal antibodies (OncoMed)

Drug Alias Namecancer therapeutics - OncoMedAnti-CSC monoclonal antibodies - OncoMedAnti-tumour-initiating cell monoclonal antibodies - OncoMedI/O#2GITRL-336B3 +[8]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionDelta-like protein 4 inhibitors

TargetsDelta-like protein 4

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesOncomed Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesOncomed Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A